Vascular endothelial growth factor (VEGF) has become a major target in cancer treatment as it promotes tumor angiogenesis. Therapy with anti-VEGF antibody bevacizumab reportedly induces high levels of circulating VEGF which may potentially contribute to resistance. Based on animal or computational models, mechanisms of VEGF induction by bevacizumab have… (More)
Figure 3: Assessment of VEGF content in platelets of mCRC patients before and after bevacizumab therapy. Blood samples were retrieved from 7 patients before (pre) and after 1-2 weeks (intra) of chemotherapy with bevacizumab treatment and analyzed for A. VEGF plasma levels, B. VEGF levels in serum, C. platelet count; D. VEGF content per platelet was then calculated by subtraction of plasma from serum values and adjusted to platelet count. E. VEGF as detected by immunoblotting in protein extracts of isolated platelets is shown for 3 of 7 investigated patients (compared to 14-3-3 “housekeeper” protein for loading control and platelet blood count of the respective sample).